1. Home
  2. PAR vs NTLA Comparison

PAR vs NTLA Comparison

Compare PAR & NTLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo PAR Technology Corporation

PAR

PAR Technology Corporation

HOLD

Current Price

$35.86

Market Cap

1.4B

Sector

Miscellaneous

ML Signal

HOLD

Logo Intellia Therapeutics Inc.

NTLA

Intellia Therapeutics Inc.

HOLD

Current Price

$9.22

Market Cap

986.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PAR
NTLA
Founded
1968
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Office Equipment/Supplies/Services
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Sector
Miscellaneous
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.4B
986.9M
IPO Year
N/A
2016

Fundamental Metrics

Financial Performance
Metric
PAR
NTLA
Price
$35.86
$9.22
Analyst Decision
Strong Buy
Buy
Analyst Count
5
22
Target Price
$64.00
$19.83
AVG Volume (30 Days)
470.7K
3.3M
Earning Date
11-06-2025
11-06-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$440,451,000.00
$57,528,000.00
Revenue This Year
$30.40
$1.96
Revenue Next Year
$12.01
N/A
P/E Ratio
N/A
N/A
Revenue Growth
39.88
33.52
52 Week Low
$31.65
$5.90
52 Week High
$77.55
$28.25

Technical Indicators

Market Signals
Indicator
PAR
NTLA
Relative Strength Index (RSI) 46.42 44.93
Support Level $36.48 $8.94
Resistance Level $37.88 $9.62
Average True Range (ATR) 1.12 0.43
MACD -0.04 0.16
Stochastic Oscillator 16.82 44.14

Price Performance

Historical Comparison
PAR
NTLA

About PAR PAR Technology Corporation

PAR Technology Corp is a foodservice technology company providing omnichannel cloud-based software and hardware solutions to the restaurant industry in three restaurant categories - quick service, fast casual, and table service - and the retail industry, including convenience and fuel retailers (C-Stores). The company's product and service offerings include point-of-sale, customer engagement and loyalty, digital ordering and delivery, operational intelligence, payment processing, hardware, and related technologies, solutions, and services. The company generates revenue from subscription service, Sale of Hardware products, and Professional Service.

About NTLA Intellia Therapeutics Inc.

Intellia Therapeutics is a gene-editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.

Share on Social Networks: